Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process CDF Review
ID number 1683

Provisional Schedule

Expected publication 12 August 2020

Project Team

Project lead Gemma Barnacle
Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Celgene (paclitaxel, nab-paclitaxel) (confidentiality agreement not signed, not participating)
  Consilient Health Ltd (carboplatin, vinorelbine) (confidentiality agreement not signed, not participating)
  • Dr Reddy’s Laboratories (docetaxel) (confidentiality agreement not signed, not participating)
  Fresenius Kabi (docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
  Fresenius Kabi Oncology (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Sun Pharma (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel)
  Seacross pharmaceuticals (docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
  Teva UK (carboplatin, cisplatin, docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
04 June 2020 Committee meeting
05 May 2020 Schedule affected by COVID-19, Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
30 January 2020 Invitation to participate
24 January 2020 In progress, Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance